This invention presents novel compositions and methods employing self-delivering siRNA (sdRNA) targeting USP10 to prevent and treat scarring and inflammation in the eye following glaucoma filtration and other intraocular pressure-lowering surgeries.
Glaucoma filtration surgery and other procedures designed to reduce intraocular pressure (IOP) are often compromised by the body's natural healing response, which leads to scarring and inflammation. This scarring can significantly diminish the effectiveness of these surgeries, resulting in treatment failure and increased risk for vision loss. Current treatment options are limited in their ability to effectively manage post-surgical scarring without causing additional side effects. Recognizing the need for more targeted and efficient therapies to control inflammation and scar formation in the eye, this technology was developed to address these challenges.
The technology utilizes a self-delivering small interfering RNA (sdRNA) specifically designed to target the USP10 gene, which plays a key role in cellular mechanisms associated with scarring and inflammation. Unlike traditional siRNA therapies that require a delivery vehicle, the sdRNA here is engineered for efficient cellular uptake without additional carriers, enhancing its therapeutic potential and reducing the risk of immune reactions or toxicity. This targeted approach allows precise modulation of gene expression in ocular tissues involved in the healing process after surgery. By inhibiting USP10 expression, the therapy reduces abnormal fibrotic responses and inflammation that lead to scar tissue formation, thereby preserving the success of IOP-lowering surgeries. The self-delivering property of the sdRNA also simplifies administration and improves bioavailability within delicate eye tissues. The technology is supported by rigorous research funded by the Syracuse VA Medical Center and leverages intellectual property managed by The Research Foundation for The State University of New York, ensuring a robust scientific and commercial foundation.
Photo for reference only, not a depiction of the invention.
• Targeted silencing of USP10 reduces pathological scarring and inflammation with high specificity.
• Self-delivering siRNA design eliminates the need for additional delivery systems, enhancing safety and ease of use.
• Minimizes adverse effects associated with conventional anti-scarring agents, improving patient outcomes.
• Preserves the effectiveness of glaucoma filtration and other intraocular pressure-lowering surgeries.
• Backed by strong institutional research and intellectual property rights, supporting development and commercialization.
• Post-operative treatment following glaucoma filtration surgery to prevent scarring and maintain surgical success.
• Therapeutic use in other ocular surgeries aimed at reducing intraocular pressure where inflammation control is critical.
• Potential extension to treating inflammatory and fibrotic conditions in various parts of the eye.
• Adjunct therapy in clinical ophthalmology to improve surgical outcomes and reduce complications.
Patent pending
Inquire for more information.
This technology is available for licensing.